Modulation of C-reactive protein expression

Details Modulation of C-reactive protein expression Modulation of C-reactive protein expression

2011-01-04

2011-01-04

McGarry, Sean R (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S375000, C536S023100, C536S024100, C536S024500

Reexamination Certificate

active

07863252

ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.

REFERENCES:
patent: 5582979 (1996-12-01), Weber
patent: 5783179 (1998-07-01), Nestor, Jr. et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6764826 (2004-07-01), Yeh et al.
patent: 6770461 (2004-08-01), Carulli et al.
patent: 6964950 (2005-11-01), Crooke et al.
patent: 7250496 (2007-07-01), Bentwich
patent: 7326693 (2008-02-01), Crooke et al.
patent: 7425545 (2008-09-01), Crooke et al.
patent: 7491815 (2009-02-01), Crooke et al.
patent: 2002/0142283 (2002-10-01), Yeh et al.
patent: 2003/0083280 (2003-05-01), Crooke et al.
patent: 2003/0207834 (2003-11-01), Dale et al.
patent: 2004/0241651 (2004-12-01), Olek et al.
patent: 2005/0014257 (2005-01-01), Crooke et al.
patent: 2006/0024727 (2006-02-01), Crooke et al.
patent: WO-96/06624 (1996-03-01), None
patent: WO-99/00418 (1999-01-01), None
patent: WO-00/11207 (2000-03-01), None
patent: WO 03/010284 (2003-02-01), None
Verma et al., Annu. Rev. Biochem. vol. 67:99-134, 1998.
Bennett et al., “Antisense oligonucleotides as a tool for gene functionalization and target validation”,Biochim. Biophys. ActaDec. 10, 1999 1489 (1):19-30.
Woo et al., “Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component”,J. Biol. Chem. Oct. 25, 1985 260 (24):13384-13388.
Agrawal, Sudhir, “Antisense oligonucleotides: towards clinical trials.”TibtechOct. 1996 14:376-387.
Arici et al., “End-stage renal disease, atherosclerosis and cardiovascular mortality: Is C-reactive protein in the missing link?”,Kidney Intl. Feb. 2001 59:407-414.
Bárány P., “Inflammation, serum C-reactive protein, and erythropoietin resistance”,Nephrol. Dial TransplantFeb. 2001 16:224-227.
Branch, Andrea D., “A good antisense molecule is hard to find”,TIBSFeb. 1998 45-50.
Gabay et al., “Acute-Phase Proteins and Other Systemic Responses to Inflammation”,New England J. of MedicineFeb. 1999 340:448-454.
Highton et al., “The Presence and Possible Significance of C-Reactive Protein in Rheumatoid Inflammation”,J. RheumatologyOct. 1985 12:871-875.
Hulthe et al., “Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study”,Clinical ScienceApr. 2001 100:371-378.
Jen et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies”,Stem CellsSep. 2000 18:307-319.
Lagrand et al., “C-Reactive Protein as a Cardiovascular Risk Factor More Than an Epiphenomenon?”,CRP and Cardiovascular DiseaseJul. 1999 100:96-102.
Lei et al., “Genomic DNA Sequence for Human C-reactive Protein”,J. Biol. Chem. Oct. 1985 260(24): 13377-13383.
Morrow et al., “C-Reactive Protein, Inflammation, and Coronary Risk”,Med. Clinics of North AmericaJan. 2000 84(1):149-161.
Ridker et al., “Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events”,N. Engl. J. Med. Jun. 2001 344(6):1959-1965.
Ridker et al., “Rapid Reduction in C-Reactive Protein with Cerivastatin Among 785 Patients with Primary Hypercholesterolemia”,CirculationMar. 2001 103:1191-1193.
Ruuskanen et al., “C-reactive protein in respiratory virus infections”,J. PediatricsJul. 1985 107:97-100.
Szalai et al., “C-Reactive Protein Structural Biology, Gene Expression, and Host Defense Function”,Immunologic Research1997 16/2:127-136.
Weintraub, Harold M., “Antisense RNA and DNA”,Scientific AmericanJan. 1990 40-46.
Westhuyzen et al., “Review: Biology and Relevance of C-Reactive Protein in Cardiovascular and Renal Disease”,Annals of Clinical&Laboratory ScienceApr. 2000 30(2):133-143.
Yudkin et al., “Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?”,AtherosclerosisFeb. 2000 148:209-214.
Chin “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
New England Biolabs, 1998/1999 Catalog, pp. 121 and 284.
Skerra et al., “Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity”,Nucleic Acids Research(1992) 20(14):3551-3554.
USPTO Office Action for U.S. Appl. No. 09/912,724 dated Sep. 20, 2002.
USPTO Final Rejection Office Action for U.S. Appl. No. 09/912,724 dated Mar. 13, 2003.
USPTO Office Action for U.S. Appl. No. 09/912,724 dated Dec. 15, 2003.
USPTO Final Rejection Office Action for U.S. Appl. No. 09/912,724 dated Jun. 9, 2004.
USPTO Final Rejection Office Action for U.S. Appl. No. 09/912,724 dated Dec. 9, 2004.
USPTO Notice of Allowance for U.S. Appl. No. 09/912,724 dated May 31, 2005 (6,964,950).
USPTO Office Action for U.S. Appl. No. 11/211,803 dated Nov. 1, 2007.
USPTO Notice of Allowance for U.S. Appl. No. 11/211,803 dated Oct. 10, 2008.
USPTO Office Action for U.S. Appl. No. 12/352,572 dated Jan. 21, 2010.
USPTO Notice of Allowance for U.S. Appl. No. 12/352,572 dated Jul. 23, 2010.
USPTO Restriction Requirement for U.S. Appl. No. 10/483,424 dated Jul. 24, 2006.
USPTO Office Action for U.S. Appl. No. 10/483,424 dated Nov. 22, 2006.
USPTO Notice of Allowance for U.S. Appl. No. 10/483,424 dated Sep. 14, 2007.
USPTO Restriction Requirement for U.S. Appl. No. 10/858,500 dated Jan. 11, 2007.
USPTO Notice of Allowance for U.S. Appl. No. 10/858,500 dated Mar. 13, 2008.
EP Supplementary Search Report for Euro Application No. 04752571.2 - 2405 dated Dec. 19, 2007.
EP Supplementary Search Report for Euro Application No. 02753388.4 dated Mar. 17, 2005.
PCT International Search Report for PCT Application No. PCT/US02/22656 dated Apr. 7, 2003 (WO 03/010284).
PCT International Written Opinion for PCT/US02/22656 dated Oct. 7, 2003 (WO 03/010284).
PCT International Search Report for PCT Application No. PCT/US2004/015576 dated Mar. 14, 2006 (WO 2005/005599).

Affiliated with

Also associated with

Rating

Modulation of C-reactive protein expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of C-reactive protein expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of C-reactive protein expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2743129